You just read:

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

News provided by

Astellas Pharma Ltd

29 Jun, 2018, 00:01 BST